HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports.

Agenus Trading Down 10.2 %

AGEN stock opened at $1.68 on Wednesday. Agenus has a 1-year low of $1.67 and a 1-year high of $19.69. The business’s 50 day moving average is $3.23 and its 200-day moving average is $3.84. The firm has a market cap of $39.29 million, a P/E ratio of -0.15 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. Sell-side analysts forecast that Agenus will post -12.55 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new stake in Agenus during the 3rd quarter valued at $55,000. Corton Capital Inc. bought a new stake in shares of Agenus during the fourth quarter worth approximately $36,000. Point72 DIFC Ltd grew its holdings in Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 11,542 shares during the period. Virtu Financial LLC bought a new stake in shares of Agenus during the 4th quarter valued at $51,000. Finally, Apollon Wealth Management LLC bought a new stake in shares of Agenus during the 4th quarter valued at $55,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.